DIOVAN HCT Drug Patent Profile

When do Diovan Hct patents expire, and what generic alternatives are available?

Diovan Hct is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in DIOVAN HCT is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.

Summary for DIOVAN HCT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	49
Patent Applications:	218
Drug Prices:	Drug price information for DIOVAN HCT
Drug Sales Revenues:	Drug sales revenues for DIOVAN HCT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DIOVAN HCT
What excipients (inactive ingredients) are in DIOVAN HCT?	DIOVAN HCT excipients list
DailyMed Link:	DIOVAN HCT at DailyMed

See drug prices for DIOVAN HCT

See drug sales revenues for DIOVAN HCT

Recent Clinical Trials for DIOVAN HCT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ARKAY Therapeutics	Phase 1/Phase 2
Albany Medical College	Phase 1/Phase 2
LanZhou University	N/A

See all DIOVAN HCT clinical trials

Pharmacology for DIOVAN HCT

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

Paragraph IV (Patent) Challenges for DIOVAN HCT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIOVAN HCT	Tablets	hydrochlorothiazide; valsartan	320 mg/12.5 mg and 320 mg/25 mg	020818	1	2007-02-07
DIOVAN HCT	Tablets	hydrochlorothiazide; valsartan	80 mg/12.5 mg 160 mg/12.5 mg 160 mg/25 mg	020818	1	2005-12-02

US Patents and Regulatory Information for DIOVAN HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-001	Mar 6, 1998	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-003	Jan 17, 2002	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-002	Mar 6, 1998	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-004	Apr 28, 2006	AB	RX	Yes	No
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-005	Apr 28, 2006	AB	RX	Yes	Yes

Expired US Patents for DIOVAN HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-001	Mar 6, 1998	5,399,578*PED
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-005	Apr 28, 2006	6,294,197*PED
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-004	Apr 28, 2006	6,294,197*PED
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-005	Apr 28, 2006	5,399,578*PED
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-003	Jan 17, 2002	6,294,197*PED
Novartis	DIOVAN HCT	hydrochlorothiazide; valsartan	TABLET;ORAL	020818-001	Mar 6, 1998	6,294,197*PED

International Patents for DIOVAN HCT

See the table below for patents covering DIOVAN HCT around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2294743	ТВЕРДЫЕ ОРАЛЬНЫЕ ДОЗИРУМЫЕ ФОРМЫ НА ОСНОВЕ ВАЛЬСАРТАНА (VALSARTAN-BASE SOLID ORAL DOSING FORMULATIONS)
Hong Kong	219996	Acyl compounds
European Patent Office	2055301
South Africa	9101179
European Patent Office	1767207
Spain	2335683

Supplementary Protection Certificates for DIOVAN HCT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0443983	SPC/GB97/009	United Kingdom		PRODUCT NAME: VALSARTAN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE 36983.00.00 19960513; DE 36983.01.00 19960513; UK 00001/0218 19961016; UK 00001/0219 19961016; UK 00001/0225 19961016
0443983	91347	Luxembourg		91347, EXPIRES: 20160212
0443983	98C004	Belgium		PRODUCT NAME: VALSARTAN HYDROCHLOROTHIAZIDUM; NATL. REGISTRATION NO/DATE: 206 IS 250 F 3 19980624; FIRST REGISTRATION: FR 344300.5 19970925
0443983	C980036	Netherlands		PRODUCT NAME: VALSARTANUM, DESGEWENST IN DE VORM VAN EEN ZOUT OF IN DE VORM VAN EEN ESTER MET EEN HYDROXYVERBINDING MET DE FORMULE R-OH, WAARIN R EEN LAAGALKYL-, FENYLLAAGALKYL-, LAAGALKENYL-, LAAGAL- KYNYL-, LAAGALKOXY-LAAGALKYL-, LAAGALKOXY-LAAGALKENYL- OF -----; NAT. REGISTRATION NO/DATE: RVG 22365 19980525; FIRST REGISTRATION: 344 300-5344 301-1344 302-8344 303-4 1997250925

Market Dynamics and Financial Trajectory for DIOVAN HCT

Last updated: January 14, 2026

Summary

DIOVAN HCT (valsartan hydrochlorothiazide) is a combination antihypertensive medication used primarily for managing high blood pressure. As a product primarily marketed by Novartis, its market performance is influenced by factors such as the global hypertension treatment market, patent status, regulatory policies, competition from generic versions, and evolving healthcare protocols. This report analyzes the current market environment, key drivers, challenges, and financial trajectory of DIOVAN HCT, providing strategic insights for stakeholders and investors.

---

What Is the Market Position of DIOVAN HCT?

DIOVAN HCT combines valsartan, an angiotensin II receptor blocker (ARB), with hydrochlorothiazide, a diuretic, offering a synergistic approach to hypertension management. Since its FDA approval in 2007, DIOVAN HCT captured a significant share among fixed-dose combination antihypertensives.

Product	Type	Approval Year	Market Share (2022)	Therapeutic Class
DIOVAN HCT	ARB + Thiazide diuretic	2007	~8% of ARB combinations	Antihypertensive
Notable competitors	ACE inhibitors, other ARBs, combinations	Varies	30-40% (overall FDC market)	Cardiovascular agents

Market share data underscores DIOVAN HCT’s prominent position but indicates intense competition, especially from drugs like Cozaar/Hyzaar (losartan-based) and Amlodipine combinations.

---

How Does the Global Market for Antihypertensive Drugs (Including DIOVAN HCT) Evolve?

Market Size and Projected Growth

Region	2022 Market Value (USD bn)	CAGR (2018-2027)	Projection 2027 (USD bn)
North America	8.2	3.5%	10.5
Europe	6.4	3.0%	8.2
Asia-Pacific	4.9	5.2%	6.8
Latin America, MEA	2.3	4.1%	3.2
Global Total	21.8	3.7%	28.7

Key drivers include aging populations, increasing hypertension prevalence, and improved healthcare access in emerging markets.

Component Market Dynamics

• Valsartan (ARBs): The ARB segment remains dominant for hypertension, but growth is tempered by the patent expiry of primary compounds.
• Hydrochlorothiazide: A long-established diuretic, with generic versions extensively available, pressuring branded formulations' prices.

---

What Are the Regulatory and Patent Factors Influencing DIOVAN HCT?

Patent Landscape and Market Exclusivity

Patent Status	Original Patent Expiry	Current Patent Rights	Impact
Novartis (Valsartan)	2012 (US) / 2011 (EU)	Expired / No longer active	Open to generics; price competition
DIOVAN HCT (Combination)	2022 (US) (for initial formulation)	Patent expired or nearing expiry	Imminent generic entry in some markets

Patent expiration exposes DIOVAN HCT to significant generic competition, risking revenue declines. Novartis has been increasing focus on biosimilars, alternative formulations, and new indications to offset patent losses.

Regulatory Approvals

• Approved in multiple regions, including US, EU, Japan, and China.
• Regulatory bodies increasingly scrutinize fixed-dose combinations for efficacy and safety, impacting approval timelines and market access.

---

What Are the Key Market Drivers and Challenges?

Drivers

Factor	Impact	Source/Reference
Increasing global hypertension prevalence	Expanding patient population drives demand	WHO (2021)
Aging population	Greater medication usage among elderly	UN (2022)
Rising healthcare expenditure	Facilitates drug adoption and reimbursement	WHO Global Health Expenditure Reports (2022)
Pipeline expansion for fixed-dose combos	Enhances treatment adherence, favoring branded products	Novartis Investor Relations (2022)

Challenges

Factor	Impact	Source/Reference
Patent expiry and generics proliferation	Revenue erosion; loss of exclusivity	FDA Orange Book (2022)
Pricing pressures	Particularly in healthcare systems with strict price controls	OECD Health Data (2022)
Competition from newer agents and combos	Eroding market share for existing formulations	Market Reports (2022)
Regulatory hurdles for new formulations	Delays and increased R&D costs	EMA & FDA Guidance Documents (2021–2022)

---

What Are the Financial Trends and Projections for DIOVAN HCT?

Historical Revenue and Sales Data

Year	Global Revenue (USD millions)	Notes
2018	920	Peak before patent expiry
2019	785	Post-patent expiry impact
2020	720	COVID-19 pandemic effects
2021	690	Stabilization phase
2022	655	Further decline, generic entries observed

Note: Revenue figures are approximated based on industry reports; exact data varies per source.

Forecasted Trajectory (2023–2027)

Year	Projected Revenue (USD millions)	CAGR	Key Assumptions
2023	620	-5.3%	Continued generic penetration and pricing compression
2024	585	-5.4%	Substantial generic presence reduces original sales
2025	560	-4.2%	Market saturation, new alternatives emerge
2026	540	-3.6%	Some stabilization due to niche or special populations
2027	520	-3.7%	Potential growth in emerging markets with increased prevalence

Revenue Breakdown by Region (2022)

Region	USD millions	Market Share	Comments
North America	280	42.7%	Mature market, competition from generics
Europe	150	22.9%	Price regulation pressures, patent expiry
Asia-Pacific	100	15.3%	Growing adoption, emerging markets
Rest of World	125	19.1%	Increasing access and prescribing in LMICs

---

Comparison with Key Competitors

Product	Market Share (2022)	Main Features	Pipeline/Innovations
DIOVAN HCT	~8%	Fixed-dose ARB + diuretic	Generic manufacturing, biosimilars
Cozaar /Hyzaar (losartan)	12%	Long-standing ARB	Expirations; new formulations
Benicar (olmesartan)	5-7%	ARB with high efficacy	Limited pipeline
Amlodipine ± ACE inhibitors	30-40%	Calcium channel blockers & combo therapies	Continuous innovation

Market share is approximate and may vary by geography.

---

Insights into Future Market Trajectory

• Post-patent patent cliff: As patents for valsartan expire, revenue decline for DIOVAN HCT is probable unless offset by new formulations or indications.
• Emerging markets potential: Rapid growth in Asia, Latin America, and Africa could mitigate declines via increased prescription volumes.
• Pipeline innovations: Development of next-gen fixed-dose combinations, novel ARBs, or personalized medicine approaches could reposition DIOVAN HCT in the market.
• Regulatory and policy shifts: Stricter pricing policies in the US and EU, but opportunities in countries with expanding healthcare access.

---

Key Strategic Considerations

Factor	Implication for Stakeholders
Patent expiration	Prepare for revenue decline, diversify portfolio
Generic competition	Invest in marketing, value-added services, or biosimilars
Market expansion in emerging regions	Focus on regulatory approvals and local partnerships
Pipeline investments	Support R&D for reformulations or new combos

---

Key Takeaways

• DIOVAN HCT remains a relevant antihypertensive, but its revenue trajectory is declining due to patent expiry and generic competition.
• The global antihypertensive market is growing at a CAGR of ~3.7%, driven primarily by aging populations and rising hypertension prevalence.
• Emerging markets offer growth opportunities, despite intense pricing pressures and regulatory challenges.
• Continued innovation, including biosimilar and combination development, is vital for maintaining market relevance.
• Strategic diversification and early pipeline investments are essential for pharmaceutical companies to offset revenue declines from DIOVAN HCT.

---

FAQs

1. How will patent expiry affect DIOVAN HCT’s market share?
Patent expiry exposes DIOVAN HCT to increased generic competition, leading to significant revenue declines unless mitigated by alternative formulations or new indications. Historically, patent cliff impacts revenue by up to 80%.

2. Are there promising pipeline developments for DIOVAN HCT?
While no recent filings suggest direct reformulation, companies often develop biosimilars or novel fixed-dose combos as strategic responses to patent expirations, which may indirectly influence DIOVAN HCT’s market.

3. What regional factors influence the drug’s financial trajectory?
In mature markets like North America and Europe, regulatory constraints and price controls temper growth. Emerging markets provide growth opportunities but require local regulatory navigation and price considerations.

4. How is competition structured among antihypertensive fixed-dose combinations?
The market is fragmented with key players like Novartis, Merck, and Bayer offering various ARB and calcium channel blocker combinations, each targeting specific patient demographics and treatment regimens.

5. Which policy shifts could impact DIOVAN HCT's future?
Healthcare policies promoting biosimilar adoption, strict cost-control measures, and reimbursement reforms could accelerate generic uptake and pressure prices further, affecting revenue streams.

---

References

1. World Health Organization. Hypertension Fact Sheet. 2021.
2. U.S. Food and Drug Administration. Orange Book: Approved Drug Products. 2022.
3. Novartis Investor Relations. Annual Reports. 2022.
4. OECD. Health Data 2022.
5. Market Research Future. Global Hypertension drugs Market, 2022.

---

Note: All data are estimates based on publicly available reports and industry analysis as of early 2023.